Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis.

摘要: We recently developed a modified Dupriez prognostic scoring system (PSS) that effectively discriminated between high-, intermediate-, and low-risk young patients (age 30 x 10(9)L(-1), platelet count or =1 10(9)L(-1) carries an independent predictive value (p=0.02), for inferior survival, in addition to provided by hemoglobin level (p=0.002), (0.02), leukocyte (p=0.16). The inclusion of the monocyte as fourth risk factor enabled construction new improved Mayo PSS; median survival was 173, 61, 26 months absence all four (low-risk), three (intermediate-risk), two less (high-risk) adverse features, respectively (p<0.0001). monocytosis validated separate database 97 with PMF from another institution.